The Hippo effector TAZ (WWTR1) transforms myoblasts and TAZ abundance is associated with reduced survival in embryonal rhabdomyosarcoma by Mohamed, Abdalla et al.
Journal of Pathology
J Pathol 2016; 240: 3–14
Published online in Wiley Online Library
(wileyonlinelibrary.com) DOI: 10.1002/path.4745
ORIGINAL PAPER
The Hippo effector TAZ (WWTR1) transforms myoblasts and TAZ
abundance is associated with reduced survival in embryonal
rhabdomyosarcoma
Abdalla Mohamed,1 Congshan Sun,2 Vanessa De Mello,1 Joanna Selfe,3 Edoardo Missiaglia,4 Janet Shipley,3
Graeme I Murray,1 Pete S Zammit2 and Henning Wackerhage1,*
1 School of Medicine, Dentistry and Nutrition, University of Aberdeen, UK
2 Randall Division of Cell and Molecular Biophysics, King’s College London, UK
3 Sarcoma Molecular Pathology Team, Divisions of Molecular Pathology and Cancer Therapeutics, Institute of Cancer Research, London, UK
4 Institut Universitaire de Pathologie de Lausanne IUP, Switzerland
*Correspondence to: H Wackerhage, Technical University of Munich, Germany. E-mail: henning.wackerhage@tum.de
Abstract
The Hippo effector YAP has recently been identified as a potent driver of embryonal rhabdomyosarcoma (ERMS).
Most reports suggest that the YAP paralogue TAZ (gene symbol WWTR1) functions as YAP but, in skeletal
muscle, TAZ has been reported to promote myogenic differentiation, whereas YAP inhibits it. Here, we investigated
whether TAZ is also a rhabdomyosarcoma oncogene or whether TAZ acts as a YAP antagonist. Immunostaining
of rhabdomyosarcoma tissue microarrays revealed that TAZ is significantly associated with poor survival in
ERMS. In 12% of fusion gene-negative rhabdomyosarcomas, the TAZ locus is gained, which is correlated with
increased expression. Constitutively active TAZ S89A significantly increased proliferation of C2C12 myoblasts and,
importantly, colony formation on soft agar, suggesting transformation. However, TAZ then switches to enhance
myogenic differentiation in C2C12 myoblasts, unlike YAP. Conversely, lentiviral shRNA-mediated TAZ knockdown
in human ERMS cells reduced proliferation and anchorage-independent growth. While TAZ S89A or YAP1 S127A
similarly activated the 8XGTIIC–Luc Hippo reporter, only YAP1 S127A activated the Brachyury (T-box) reporter.
Consistent with its oncogene function, TAZ S89A induced expression of the ERMS cancer stem cell gene Myf5
and the serine biosynthesis pathway (Phgdh, Psat1, Psph) in C2C12 myoblasts. Thus, TAZ is associated with poor
survival in ERMS and could act as an oncogene in rhabdomyosarcoma.
© 2016 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain
and Ireland.
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Introduction
Yap (gene symbol Yap1) and Taz (gene symbol Wwtr1)
are transcriptional co-factors that regulate gene expres-
sion mainly by binding Tead1–4 [1,2]. Yap and Taz are
not only regulated by the Hippo pathway [3] but are also
additionally targeted by a network of other signalling
molecules, including PIK3CA [4], KRAS [5–7] and
CTNNB1 (encoding β-catenin) [8]. Importantly, these
crosstalking genes are affected by recurrent pan-cancer
mutations [9], including in embryonal rhabdomyosar-
coma (ERMS) [10].
Persistent Yap hyperactivity, as a consequence of
expressing a constitutively active YAP1 S127A mutant,
results in tumours of the liver [11] and skin in mice [12].
Constitutive Yap hyperactivity in activated muscle stem
(satellite) cells causes ERMS-like tumours with
high penetrance in mice [13]. Whilst no YAP1 or
WWTR1 point mutations have been reported for ERMS,
mutations of several cancer genes that can crosstalk/
interact with YAP or TAZ have been identified in
sequencing studies [10]. In addition, we and oth-
ers have reported YAP1 copy number gains in some
rhabdomyosarcomas [13,14].
Yap and Taz both have WW domains and can bind all
Tead transcription factors [1,2], but differ significantly
in their function. This is especially evident in knockout
mice, as a Yap1 knockout is embryonal lethal at E8.5
[15], whereas some Wwtr1 knockout mice are born
but later develop glomerulocystic kidney disease [16].
Nonetheless, TAZ, like YAP, has been associated with
cancer [17,18], suggesting that both YAP1 and WWTR1
can act as oncogenes.
In the skeletal muscle lineage, high levels of YAP
activity in muscle fibres cause myopathy [19], but
more moderate increases induce skeletal muscle fibre
hypertrophy [20,21]. In myoblasts and satellite cells,
active Yap potently promotes proliferation [22,23] and
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persistent YAP hyperactivity transforms satellite cells
to cause ERMS [13]. In contrast to Yap, active Taz
has been reported to promote myogenic differentia-
tion [24]. The promotion of myogenic differentiation
would be anti-tumourigenic, because myoblasts within
a rhabdomyosarcoma tumour fail to differentiate into
post-mitotic myocytes/myotubes [25]. This might sug-
gest context-dependent function of TAZ as either an
oncogene or tumour suppressor. Similarly, whilst YAP
and TAZ generally function as oncogenes [17,18], it has
been reported that YAP can function as a tumour sup-
pressor in the intestine [26], although there is no con-
sensus on this [27].
The aim of this study was to test whether TAZ abun-
dance is associated with survival in rhabdomyosarcoma
and to characterize the cancer-specific functions of TAZ
in myoblasts and human ERMS cells, to identify TAZ
as either an oncogene and YAP agonist or as a tumour
suppressor.
Materials and methods
Human rhabdomyosarcoma tissue microarrays
For the rhabdomyosarcoma tissue microarrays,
formalin-fixed, paraffin-embedded diagnostic tumour
material from 79 patients with RMS was collected
from UK centres through the Children’s Cancer and
Leukaemia Group (Local Research Ethics Commit-
tee Protocol Nos. 1836 and 2015 and Multi-Regional
Research Ethics Committee 06/4/71, with consent where
required). The histology of cases was confirmed, by
review according to World Health Organization guide-
lines, to be 25 alveolar and 54 embryonal. Cores of
0.6mm diameter from three or more defined regions of
tumour blocks were used to construct a tissue microar-
ray [28]. A previously described tissue microarray was
also used, containing material from 60 alveolar and
171 embryonal cases [29]. Immunohistochemistry and
assessment of the arrays is reported in Supplementary
materials and methods (see supplementary material).
Cell culture
Mouse C2C12 and human RD and RH30 cells were
cultured in Dulbecco’s minimum essential medium
(DMEM; Sigma), supplemented with 10% fetal calf
serum (FCS; Hyclone). To induce differentiation, cells
were cultured in growth medium until confluence, then
the medium was switched to DMEM with 2% horse
serum (Hyclone). Human cells [30] were cultured
in skeletal muscle cell growth medium (Promocell,
C-23160) and passaged when needed.
Retroviral and lentiviral expression vectors
and transduction methods
Wild-type TAZ and TAZ S89A cDNA were subcloned
into a pMSCV–IRES–eGFP [31] retroviral expres-
sion backbone from plasmid DNA (Addgene Plasmids
24809 and 24815, deposited by Dr Jeff Wrana), creating
pMSCV–3x Flag TAZ–IRES–eGFP and pMSCV–3x
Flag–TAZ S89A–IRES–eGFP constructs. Empty vec-
tor pMSCV–IRES–eGFP was used as control vector.
Retroviruses [23] and lentiviruses [32] were packaged
in HEK293-T cells, as described previously. Cells were
transduced by incubation in diluted viral supernatant
(1:4) until assayed.
Immunocytochemistry
Fixed cells were permeabilized with 0.5% v/v
Tween-20/PBS for 6min and blocked with 20%
v/v goat serum/PBS for 30min. The cells were incu-
bated overnight at 4 ∘C with the primary antibodies
mouse anti-MyHC (DSHB, clone MF20; 1:400), mouse
anti-Ki67 (Cell Signaling, 9449; 1:400) and chicken
anti-GFP (Abcam, ab13970; 1:1000). Species-specific,
fluorochrome-conjugated secondary antibodies were
applied for 90min at room temperature and the slides
were mounted with Vectashield medium with DAPI
(Vector laboratories). Proliferation of RD cells was
assessed by EdU (5-ethynyl-2′-deoxyuridine) incor-
poration, using 10 μM EdU for 4 h in growth medium.
The Click-iT® EdU kit (Invitrogen) was used to detect
incorporated EdU, following the manufacturer’s instruc-
tions. Quantification of Ki67- and EdU-positive cell
percentages and myogenic fusion index is reported in
Supplementary materials and methods (see supplemen-
tary material).
Western blotting
Cells were lysed in modified RIPA buffer supple-
mented with protease cocktail and phosphatase
inhibitors (Sigma). Whole-cell lysates were sepa-
rated by SDS–PAGE electrophoresis and transferred
to a nitrocellulose membrane. The membranes were
then probed with mouse anti-Yap/Taz (Santa Cruz,
101199; 1:100), rabbit anti-phospho Yap Ser127 (Cell
Signalling, 9411; 1:1000) or rabbit anti-Taz (Sigma,
HPA007415; 1:1000). Primary antibodies were then
visualized using species-specific conjugated secondary
antibodies (Invitrogen) and digitally imaged.
Anchorage-independent agarose transformation
assay
Cells (1× 104) were added to 2ml growth medium with
0.5% agarose (Promega) and layered onto 2ml 0.35%
agarose-supplemented medium in six-well plates. The
cells were fed with 1ml growth medium weekly for 4–6
weeks, after which colonies were fixed with 10% acetic
acid/10% methanol for 10min, followed by staining
with 0.005% crystal violet for 1 h, and counted using
a light microscope. Colony numbers and sizes were
determined using ImageJ v. 1.43 (NIH, USA).
RNA extraction and reverse transcription (RT)–qPCR
Total RNA was isolated from cultured cells using Trizol
reagent (Invitrogen). cDNA was synthesized by reverse
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transcription, using Superscript II (Invitrogen), and sub-
jected to real-time PCR with gene-specific primers (see
supplementary material, Table S1) in the presence of 1×
Light Cycler 480® probes master mix (Roche). Relative
abundance of mRNAwas calculated by normalization to
Gapdh, using mouse Gapdh endogenous control (Life
Technologies, 4352339E) or human GAPDH (see sup-
plementary material, Table S1).
Luciferase reporter assays
For the luciferase reporter assay, retrovirally-transduced
C2C12 myoblasts or lentivirally-transduced RD cells
were seeded in six-well plates overnight. Luciferase
reporters (see supplementary material, Table S2) and
TK–Renilla plasmid were co-transfected and 24 h later
cells were lysed and luciferase activity assayed using
the Dual-Luciferase Reporter Assay System (Promega),
following the manufacturer’s instructions. All luciferase
activities were normalized to Renilla activity.
Bioinformatic analyses
For Figure 1E, we determined copy number gains
of the WWTR1 locus (chromosome 3q24-q24) by
re-analysing the Innovative Therapies for Children
with Cancer/Carte d’Identite ́ des Tumeurs (ITCC/CIT)
dataset [33]. For Figures S2A and S4B (see supple-
mentary material) the gene expression profile of 235
rhabdomyosarcoma patients from two publicly available
datasets were analysed: the first contained 101 samples
(Innovative Therapies for Children with Cancer/Carte
d’Identite des Tumeurs (ITCC/CIT) [33]; the second
134 samples [Children’s Oncology Group/Intergroup
Rhabdomyosarcoma Study Group (COG/IRSG)] [34].
Other non-rhabdomyosarcoma datasets for these figures
were as described in Tremblay et al [13]. For Figures
S2B and S4A (see supplementary material), the Cancer
Cell Line Encyclopaedia [35] search engine was used
(http://www.broadinstitute.org/ccle/home/26463/). For
Figure S3A (see supplementary material), WWTR1 and
YAP1 mutation and copy number data were plotted
using cBioPortal (http://www.cbioportal.org/) [36,37].
For Figure S3B (see supplementary material), selected
supplementary data from the dataset of Gentles et al
[38] were used.
Statistical analysis
Data were analysed using GraphPad Prism v.
5.0 (GraphPad Software) and were presented as
mean± standard deviation (SD). Statistical compar-
isons were done using one-way ANOVA or unpaired
t-test. The Bonferroni multiple comparison test was
applied following ANOVA to determine significant
differences between the groups. For all experiments,
statistical analysis was conducted on raw data col-
lected from at least three independent experiments,
performed on different occasions with three replicates
each; p≤ 0.05 was considered significant.
Results
To test whether TAZ protein abundance is associated
with clinical outcomes in rhabdomyosarcoma, we
immunostained a human rhabdomyosarcoma tissue
microarray containing 206 ERMS and 76 ARMS cases
for TAZ, using the HPA007415 Sigma antibody, pre-
viously used to immunostain breast cancer samples
[39], and assessed TAZ levels and location (Figure 1A,
C). Nuclear staining for TAZ protein was observed
in 22.8% (47/206) of ERMS samples (Figure 1C).
Survival curves for TAZ-positive and -negative samples
were generated for tumours where data were available,
and showed lower survival for TAZ-positive rhab-
domyosarcomas (Figure 1B). Survival was significantly
lower for TAZ-positive ERMS (p= 0.032) and there
was also a trend for lower survival in TAZ-positive
ARMS (p= 0.094) when compared to TAZ-negative
ERMS and ARMS, respectively. Additionally, we
measured WWTR1 mRNA levels in human myoblasts
[30], RD (ERMS) and RH30 (ARMS) cells [40] by
RT–qPCR and also performed a western blot to com-
pare TAZ protein levels in these cell lines. RD cells
had the highest WWTR1 mRNA and TAZ protein abun-
dance, compared to RH30 cells and human skeletal
myoblasts (Figure 1D). Re-analysis of a previously
publicly available dataset [33] revealed copy number
gains of the region of Chromosome 3 that incor-
porates the WWTR1 locus (chromosome 3q24-q24)
in 12% (five of 43) of human fusion gene-negative
rhabdomyosarcomas, but not in fusion gene-positive
ARMS (Figure 1E). Comparison with expression
data showed that the expression level of the WWTR1
gene correlates with the copy number of its chromo-
somal locus, with a Pearson correlation coefficient
(r)= 0.31 for fusion gene-negative rhabdomyosarcoma
(p= 0.046).
Consistent with the association of TAZ immunos-
taining with ERMS rather than ARMS, WWTR1
expression was also higher in ERMS than in
PAX3/7–FOXO1-positive ARMS and human skeletal
muscle (see supplementary material, Figure S2A).
To compare expression of WWTR1 in RD and RH30
cells and soft tissue sarcomas generally in relation to
other tissue cancer cell lines, we plotted their mRNA
levels using the Cancer Cell Line Encyclopedia dataset
(see supplementary material, Figure S2B) [35]. This
revealed that WWTR1 and YAP1 (not shown) were
highly expressed in most cancer cell lines, with the
exception of low expression in blood cancers. This
analysis confirmed that WWTR1 expression was high
in ERMS cells consistent with higher expression in the
RD (ERMS) than RH30 (ARMS) cell lines (Figure 1D).
We also plotted the pan-cancer mutational profile
for WWTR1 and YAP1 using cBioPortal [36,37]. Addi-
tionally, we displayed a meta-z value for WWTR1 and
YAP expression as a measure of their association with
survival in 18 000 cases of human cancer [38] (see sup-
plementary material, Figure S3A, B). These analyses
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Figure 1. TAZ is associated with reduced survival in ERMS. (A) Examples of rhabdomyosarcoma, showing either negative or positive TAZ
immunostaining; positive TAZ staining shows both strong nuclear and cytoplasmic TAZ staining, shown at higher magnification in Figure
S1A (see supplementary material); scale bar= 50 μm. (B) Percentage survival of ERMS and ARMS patients who had sufficient follow-up to
be included in the survival analysis scored positive and negative for TAZ; the table shows patients at each given time point, ie those who
had not died or had been lost to follow-up. (C) Abundance and localization of TAZ in ERMS and ARMS. (D) (Left) Expression of WWTR1
and protein abundance in cultured human skeletal myoblasts, RD and RH30 cells; data are presented as mean± SD, where n= 3 and *
denotes a significant difference (p< 0.05), as assessed using one-way ANOVA when compared to human myoblasts. (E) Genomic regions
on chromosome 3 that include the WWTR1 locus were gained in five of 43 (12%) fusion-negative rhabdomyosarcoma samples [33].
revealed few point mutations in TAZ and YAP1, but some
copy number alterations were found (see supplementary
material, Figure S3A). Across all cancers, expression
of TAZ and YAP1 was only moderately associated with
poor survival (see supplementary material, Figure S3B)
[38]. BIRC5 and KLRB1 were also plotted as reference
genes whose expression is most associated with poor
and good survival, respectively (see supplementary
material, Figure S3B).
The positive correlation between high WWTR1
expression and poor survival prompted us to test
whether expression of wild-type TAZ or constitutively
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Figure 2. TAZ and TAZ S89A enhance proliferation in C2C12 myoblasts. (A) pMSCV map and schematic drawing of the control vector, TAZ
and TAZ S89A-encoding inserts. (B) Validation of human WWTR1 expression and TAZ protein levels in cells transduced with TAZ or TAZ
S89A-encoding retroviruses. (C) Example images of C2C12 myoblasts transduced with control vector, TAZ or TAZ S89A-encoding retroviruses
and immunostained 2 days later for the proliferation marker Ki67, and quantification of the proportion of Ki67-expressing myoblasts; scale
bar= 50 μm; data are expressed as mean± SD, where n= 3 and * denotes a significant difference (p< 0.05), as assessed using one-way
ANOVA when compared to control.
active TAZ S89A was sufficient to transform C2C12
mouse myoblasts. We subcloned the pMSCV retroviral
backbone (containing an internal ribosomal entry site
to allow parallel expression of eGFP) with flag-tagged
human TAZ and TAZ S89A, with pMSCV–IRES–
eGFP serving as a control (Figure 2A). Retroviral con-
structs were verified by RT–qPCR, where expression
of human WWTR1 mRNA was detected from both the
TAZ and TAZ S89A-encoding retroviruses (Figure 2B).
Western blot analysis of transduced cells also confirmed
the generation of wild-type TAZ and constitutively
active TAZ S89A from the retroviral constructs
(Figure 2B). The over-expression of TAZ mutants
in C2C12 myoblasts or knockdown of TAZ in RD cells
did not affect YAP abundance (Figures 2B, 5A).
To measure the proliferation of C2C12 myoblasts,
we transduced myoblasts with the TAZ or TAZ
S89A-encoding retroviruses and immunostained for
the proliferation marker Ki67. Expression of TAZ
significantly increased the proportion of Ki67-positive
cells by 59% and TAZ S89A increased it by 96%,
compared to control vector (Figure 2C), revealing that
enhanced TAZ levels and activity promotes proliferation
in skeletal myoblasts.
Next, we tested the effects of TAZ or TAZ S89A
expression on C2C12 myoblast colony formation
on soft agar, as a measure of transformation. TAZ
expression significantly increased the mean number of
colonies by 12-fold and TAZ S89A by 18-fold when
compared to control vector (Figure 3A). These colonies
were also bigger in size with TAZ or TAZ S89A expres-
sion (Figure 3A). TAZ or TAZ S89A expression did
not impair myogenic differentiation in immortalized
C2C12 myoblasts (Figure 3B), consistent with earlier
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Figure 3. TAZ or mutant TAZ S89A promote transformation of C2C12 myoblasts. (A) Example images showing colony formation in C2C12
myoblasts transduced with empty vector, TAZ or TAZ S89A-encoding retroviruses; TAZ or TAZ S89A significantly increase colony number and
size when compared to control vector. (B) Expression of TAZ or TAZ S89A did not prevent myogenic differentiation of C2C12 myoblasts when
compared to control (empty vector). TAZ or TAZ S89A, actually significantly increased the fusion index after 72 h. Data are expressed as
mean± SD, where n= 3 and * indicates a significant difference (p< 0.05) using one-way ANOVA when compared to control; scale bar= (A)
500 μm; (B) 50 μm
findings [22], and in marked contrast to the inhibitory
effects of YAP1 S127A on differentiation [24].
To test whether the different functions of TAZ and
YAP can be explained by different transcriptional activ-
ities, we used a panel of Hippo signalling reporters
(see supplementary material, Table S2), including the
8XGTIIC Hippo [41,42], CTGF (connective tissue
growth factor; a Hippo reporter with three Tead binding
sites from this gene [32]) and a Brachyury reporter
(as YAP has been reported to bind TBX5 in tumour
cell lines [8]). C2C12 myoblasts were infected with
retroviral vectors encoding wild-type TAZ, TAZ S89A
or YAP1 S127A mutants and then transfected with
reporter constructs. Measuring normalized luciferase
activity from the reporter constructs revealed that
while mutant TAZ S89A or YAP1 S127A activated
the 8XGTIIC reporter by similar amounts, only YAP1
S127A significantly enhanced the activity of the CTGF
and Brachyury reporters (Figure 4A).
Next, we searched for transcriptional mechanisms
by which TAZ S89A drives tumour-related changes in
myoblasts. To do this we retrovirally expressed TAZ
or TAZ S89A and used RT–qPCR to measure expres-
sion of the YAP activity markers Ctgf , the zebrafish
embryonal cancer stem cell gene Myf5 [43] and Phgdh,
Psat1 and Psph of the serine biosynthesis pathway,
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Figure 4. TAZ S89A activates genes associated with human cancer. (A) Effects of TAZ, mutant TAZ S89A and YAP S127A expression on Hippo
pathway reporter constructs 8XGTIIC–Luc, CTGF–Luc and Brachyury–Luc in C2C12 myoblasts. (B) Validation of the expression of human
WWTR1 and effects of TAZ or TAZ S89A expression in C2C12 myoblasts on expression of Ctgf , Myf5, Phgdh, Psat1 and Psph. Data are
expressed as mean± SD, where n= 3 and * indicates a significant difference (p< 0.05) when compared to control using one-way ANOVA
previously linked to remodelling of metabolism in can-
cer [44,45] and induced by Yap in myoblasts [23] and
Yap-driven ERMS [13]. TAZ S89A drove increased
expression of the cancer-related genes Phgdh, Psat1,
Psph and Myf5, although Ctgf mRNA levels were
unchanged (Figure 4B). This effect of TAZ on Myf5
in C2C12 myoblasts is consistent with the 8.8-fold
up-regulation in YAP1 S127A-driven ERMS [13] and
highMYF5 expression in the RH18 (ERMS) cell line and
in human ERMS compared to skeletal muscle or human
ARMS (see supplementary material, Figure S4). Thus,
constitutive active TAZ can drive expression of key rhab-
domyosarcoma and cancer-related genes.
To test whether TAZ is critical for the tumour char-
acteriztics of RD cells, where TAZ protein levels
are high (Figure 1D), we investigated the effects of
lentiviral shRNA-mediated TAZ knockdown (see sup-
plementary material, Table S3) on the proliferation and
differentiation of RD cells. As expected, RD cells
transduced with TAZ shRNA-encoding lentiviruses had
less TAZ protein and expressed lower levels of TAZ
mRNA than control cells transduced with scrambled
shRNA sequences. Again, manipulation of TAZ pro-
tein levels did not alter YAP1 mRNA or YAP protein
levels (Figure 5A). WWTR1 shRNA-transduced RD
cells cultured in soft agar formed significantly fewer
colonies when compared to control cells transduced
with scrambled shRNA sequences, which were also
smaller (Figures 5B). TAZ knockdown in RD cells
also reduced the proliferation rate, as measured by
EdU incorporation (Figure 5C). Immunostaining for
MyHC after TAZ knockdown in RD cells revealed
that reduction of TAZ levels did not affect myogenic
differentiation (Figure 6A).
Next, we performed qPCR analyses to assess the
effect of TAZ knockdown in RD cells on expression
© 2016 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2016; 240: 3–14
on behalf of Pathological Society of Great Britain and Ireland. www.pathsoc.org www.thejournalofpathology.com
10 A Mohamed et al
Figure 5. TAZ knockdown reduces proliferation and transformation behaviour in RD cells. (A) Transduction of RD cells with scrambled or
TAZ shRNA-encoding lentiviruses for 24 h followed by 72 h puromycin selection reduced TAZ protein and mRNA but did not affect YAP
expression, as assessed by western blot and qPCR. (B) Example images showing number of colonies and their size with RD cells transduced
with either scrambled or TAZ shRNA; TAZ knockdown significantly reduced colony number when compared to control. (C) Example images
of RD cells transduced with scrambled or TAZ shRNA lentiviruses and incorporation of EdU visualized and quantified. Data are expressed as
mean± SD, where n= 3 and * denotes a significant difference (p< 0.05) when compared to control using unpaired t-test; scale bar= (B)
500 μm; (C) 50 μm
of some known Hippo target genes. TAZ knockdown
significantly reduced the expression of CYR61 by∼75%
and BIRC5 (survivin) by ∼90% when compared to con-
trols (Figure 6B). There was also a trend for reduced
E2F1 expression after TAZ knockdown, but this did
not reach significance (p= 0.06) (Figure 6B). Further-
more, TAZ knockdown in RD cells significantly reduced
the transcriptional activity of the 8XGTIIC (TEAD)
luciferase reporter by∼70% (Figure 6B), suggesting that
TEADs are key targets of TAZ in RD cells. Together,
these data further indicate that TAZ acts as an oncogene
in RD cells.
Discussion
Our data suggest that TAZ functions as an oncogene
in ERMS. However, whilst YAP1 S127A expression
blocks myogenic differentiation, we confirm that TAZ
S89A expression does not inhibit differentiation, in
line with an earlier study [24]. Consistent with its
oncogene function, TAZ drives expression of the ERMS
stem cell factor Myf5 [43] and of members of the
serine biosynthesis pathway (Phgdh, Psat1 and Psph),
which have been linked to metabolic remodelling
in cancer [44,45]. Moreover, knockdown of TAZ in
human ERMS RD cells reduces both proliferation and
anchorage-independent growth.
WWTR1 mRNA is more highly expressed in ERMS
than in PAX3/7–FOXO1A-positive ARMS and differen-
tiated skeletal muscle. Similarly, TAZ protein is detected
in 55% of human ERMS but only in 36% of human
ARMS cases. These observations, and our previous
results that identified more YAP immunostaining in
ERMS than ARMS, suggest that YAP and TAZ are
generally more abundant in ERMS than in ARMS. Copy
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Figure 6. TAZ knockdown reduces the levels of known oncogenes in RD cells. (A) shRNA-mediated knockdown of TAZ in RD cells had no
effect on myogenic differentiation, as shown by immunostaining with MyHC. (B) Expression of CYR61, E2F1, BIRC5 and activity of the
8XGTIIC–Luc reporter was assessed in RD cells after TAZ knockdown. Data are expressed as mean± SD, where n= 3 and * indicates a
significant difference (p< 0.05) when compared to control using unpaired t-test; scale bar= 50 μm
number gains can explain the higher abundance of YAP
in some ERMS cases [13,14] and here we additionally
report copy number gains of the WWTR1 locus in 12%
of ERMS and fusion gene-negative ARMS cases, but not
in any ARMS case [46].
We previously reported that YAP abundance and
activity are associated with higher grades and reduced
survival in ERMS [13]. Here we show that the abun-
dance of TAZ protein is similarly associated with
reduced survival in ERMS (p= 0.032) and that there
is a trend for ARMS (p= 0.094), suggesting that TAZ
is functionally important, especially in ERMS. Similar
associations between TAZ abundance and poor sur-
vival have been reported for human breast cancer [39],
non-small cell lung cancer [47], hepatocellular carci-
noma [48] and colorectal cancer [49]. In breast cancer,
higher Hippo activity was detected in higher-grade
breast cancers and in this cancer TAZ was also linked
to cancer stem cells and drug resistance [39].
Rhabdomyosarcomas comprise cells/myoblast-like
cells that fail to differentiate into post-mitotic, multin-
ucleated myotubes and fully mature muscle fibres [25].
Intriguingly, TAZ expression increases duringmyogenic
differentiation of human fetal myoblasts and TAZ has
been reported to promote myogenic differentiation [24],
whereas YAP inhibits differentiation [20,23]. In our
experiments, TAZ S89A and TAZ expression increased
proliferation and soft agar growth of C2C12 myoblasts,
whereas TAZ knockdown in RD cells reduced prolifera-
tion, soft agar growth, activity of the 8XGTIIC reporter
and expression of genes such as CYR61 and BIRC5.
Collectively, this suggests that TAZ acts, like YAP [13],
as an oncogene in the muscle lineage.
Intriguingly, whilst YAP1 S127A (but not YAP)
prevents differentiation of C2C12 myoblasts [22], TAZ
S89A and TAZ enhanced myogenic differentiation into
multinucleated, myosin heavy chain-positive myotubes.
This context-dependent, seemingly contradictory
pro-proliferation and pro-differentiation function of
TAZ is reminiscent of the function of Notch in the
muscle lineage, as Notch can affect both the quiescence
and proliferation of muscle stem cells, depending on
the context and timing [50].
To identify potential mechanisms by which TAZ
exerts its effects, we conducted reporter and gene
expression experiments. TAZ and YAP mainly bind
TEAD transcription factors that regulate gene expres-
sion through binding to CATTCC/GGAATG motifs
(MCAT; TEADs bind both strands [1,2]). Addition-
ally, YAP and TAZ have been reported to bind other
transcription factors, including TBX5 [8,51], which
has been identified as an important interaction in
cancer [8]. To identify putative mechanisms for the
different actions of YAP and TAZ, we investigated
the effect of TAZ and YAP mutants on 8XGTIIC,
CTGF and Brachyury (T-box) reporters. This revealed
that, whilst TAZ S89A and YAP1 S127A similarly
activated the 8XGTIIC reporter [41,42], only YAP1
S127A was able to significantly activate the CTGF [32]
and Brachyury reporters. This suggests that TAZ and
YAP have common and unique effects on transcription,
which could explain the difference in function seen in
skeletal muscle and in Yap1 [15] and Wwtr1 knockout
mice [16].
Finally, we determined the effect of wild-type TAZ or
TAZ S89A expression on genes that we had previously
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identified as Yap-regulated genes in myoblasts [23] and
Yap-driven ERMS [13].
CTGF is commonly used as a marker of Hippo activ-
ity, as it has three MCAT Tead-binding sites in its prox-
imal promoter [32]. We found no effect of TAZ or TAZ
S89A expression on Ctgf expression. In contrast to this,
YAP S127A increases Ctgf expression in myoblasts
[23] but Ctgf expression is not increased in Yap-driven
ERMS [13]. This suggests that Ctgf expression is not a
universal marker of high YAP/TAZ-Tead activity.
We found that TAZ and TAZ S89A increased Myf5
expression. This is functionally relevant, as Myf5
is a cancer stem cell gene in zebrafish ERMS [43].
Intriguingly, the ECR111 enhancer of Myf5 harbours
a Tead-targeted MCAT motif [52] which could act as
a target for TAZ. Previously we found that especially
YAP1 S127A increased Myf5 expression in C2C12
myoblasts and Yap-ERMS [13]. Together this suggests
that YAP and TAZ may contribute to the maintenance
of a cancer stem cell population in ERMS through the
expression of Myf5.
Cancer cells remodel their metabolism so that gly-
colytic intermediates and other metabolites are chan-
nelled into biosynthetic pathways to support growth
and proliferation. This is known as aerobic glycoly-
sis or the Warburg effect [53]. The serine biosynthe-
sis pathway, and especially the first enzyme of this
pathway, Phgdh, have previously been identified as
proliferation-limiting genes in cancer, and some copy
number gains of PHGDH have been identified in some
cancers [44,45]. We found that TAZ S89A significantly
increased expression of Phgdh, Psat1 and Psph, the
three enzymes of the serine biosynthesis pathway. The
TAZ-driven induction of the serine biosynthesis path-
way is a novel mechanism of metabolic remodelling
and complements previous studies that linked Hippo sig-
nalling to the Warburg effect in cancer [54,55].
Interestingly, YAP has recently been shown to
inversely regulate TAZ protein, but this inverse rela-
tionship is unidirectional, only being observed upon
modulation of YAP and not TAZ [56], This inverse
relationship extends to skeletal muscle, since over-
expression of TAZ mutants in C2C12 myoblasts or
knockdown of TAZ in RD cells do not seem to have
compensatory effects on YAP in RD cells.
In summary, our data identify TAZ as an oncogene in
the muscle lineage. This further supports an important
role for the Hippo pathway in both ERMS [13], ARMS
[57] and sarcoma in general [58,59].
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